Could a blood pressure drug slow a leaky heart valve?
NCT ID NCT07539298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether valsartan, a common blood pressure drug, can slow the worsening of atrial functional mitral regurgitation (a leaky heart valve) in 50 adults with normal heart pumping function. Participants take either valsartan or a placebo twice daily for 12 months, with regular heart imaging and safety checks. The goal is to see if the drug reduces valve damage and improves symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Valsartan (a blood pressure medication)
What this could lead to
If it works, this could point toward a way to slow the progression of atrial mitral regurgitation without surgery.
What could go wrong
This is a small pilot study with only 50 participants, so results may not apply to everyone. Valsartan may not slow the condition and could cause side effects like low blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FUNCTIONAL MITRAL REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••